{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1041.2","value":"2415.9"},{"groupId":"OG001","spread":"2434.6","value":"2918.5"},{"groupId":"OG002","spread":"190.14","value":"2804.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"AUC is a measure of the serum concentration of LMB-100 over time. It is used to characterize drug absorption.","dispersionType":"Standard Deviation","groups":[{"description":"LMB-100 100 mcg/kg\n\nLMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG000","title":"Dose Escalation Dose Level 1 LMB-100 100 mcg/kg"},{"description":"LMB-100 140 mcg/kg\n\nLMB-100: Arms 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG001","title":"Dose Escalation Dose Level 2 LMB-100 140 mcg/kg"},{"description":"LMB-100 at optimal dose plus tofacitinib - 100 mcg/kg LMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG002","title":"Dose Expansion LMB-100, 100 mcg/kg"}],"paramType":"MEAN","populationDescription":"3/16 participants from both cohorts were not analyzed they did not have AUC(INF) of LMB-100 measured during the 1st cycle (i.e., Not evaluable)","reportingStatus":"POSTED","timeFrame":"Pre-administration, end-of-infusion, then 1, 2, 4, 8-10, 12-16 hours post- LMB-100 during cycle 1 (each cycle = 21 days)","title":"Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF)) of LMB-100","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}